Share ownership MedinCell S.A.

MEDCL

FR0004065605

Pharmaceuticals

Real-time Euronext Paris Other stock markets 04:39:11 2026-01-15 am EST			5-day change	1st Jan Change
27.28 ^EUR	-1.09%		+6.00%	+7.94%

Dec. 10	Medincell Narrows Operating Loss in First Half
Dec. 10	MedinCell Says Partner Filed US FDA Application for Once-monthly Schizophrenia Treatment	MT

Share class: MedinCell S.A.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	29,120,260	17,954,923 ( 61.66 %)	10,250 ( 0.0352 %)	61.66 %

Major shareholders: MedinCell S.A.

Name	Equities	%	Valuation
Mirova SA (Investment Management) 7.373 %	2,458,744	7.373 %	73 M €
Dassault Family 5.009 %	1,670,426	5.009 %	49 M €
Anh Nguyen 4.367 %	1,456,343	4.367 %	43 M €
Adage Capital Management LP 3.777 %	1,259,424	3.777 %	37 M €
BNP Paribas Développement SA 3.271 %	1,090,688	3.271 %	32 M €
Saint Olive Gestion SNC 1.016 %	338,843	1.016 %	10 M €
Montpensier Arbevel SAS 0.8946 %	298,296	0.8946 %	9 M €
Société Générale Investment Solutions (France) 0.4048 %	135,000	0.4048 %	4 M €
Mandarine Gestion SA 0.3233 %	107,800	0.3233 %	3 M €
Amplegest SAS 0.203 %	67,702	0.203 %	2 M €
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	18.33%
Individuals	9.38%
MedinCell SA	0.01%
Unknown	72.28%

Based on 1000 largest holdings

Geographical origin of shareholders

France	14.56%
Individuals	9.38%
United States	3.78%

Based on 1000 largest holdings

MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeqTM). As of March 31, 2025, the company had a portfolio of 2 products in phase III clinical development and 3 products in preclinical development.

Employees

145

Sector

Pharmaceuticals

Calendar

Jun. 15 - Q4 2026 Earnings Release (Projected)

More about the company